Opportunities Outside of Diabetes and Obesity Additional Indications for Exploration Additional Indications for Exploration As new companies look to enter the incretin mimetic space, and existing players seek to expand their portfolios, its increasingly important to look beyond diabetes and obesity
Tirzepatides evidence depth is unmatched today twelve Phase 3 trials across two disease programmes, a published cardiovascular outcomes trial in more than thirteen thousand patients, and three FDA approvals on label
The upper thigh also has a lower concentration of nerve endings compared to the abdomen, which many patients report as more comfortable for weekly injections
Counterfeit and international sourcing add further danger
Each one is entirely preventable
Other examples of program engagement include posting on peer discussion boards, completing lessons, and tracking meals, weight, and other metrics